Abstracts tagged "Systemic sclerosis"

Abstract Number: 0678 • ACR Convergence 2025
Targeting the plasma cell niche in systemic sclerosis: A case series about the bispecific anti-BCMAxCD3 antibody teclistamab in severe, treatment-refractory patients
Andrea-Hermina Györfi¹, Ayla Nadja Stuetz², Christina Duesing³, Laura-Marie Lahu⁴, Franca Sophie Deicher⁵, Yi-Nan Li⁶, Celine van Saan⁵, Alexandru-Emil Matei⁷, Alexander Hoelscher⁵, Peter-Martin Bruch⁸, Sarah Koziel⁸, Manuel Roehrich⁹, Mareike Cramer¹⁰, Bernhard Homey⁵, Bjoern Buehring¹¹, Alexander Kreuter¹², Aleksandar Radujkovic⁵, Claus Peter Heußel¹³, Hanns-Martin Lorenz¹⁴, Ricardo Grieshaber-Bouyer¹⁵, Georg Schett¹⁶, Jörg Distler¹⁷ and Wolfgang Merkt¹⁸, ¹Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ²Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, ³Klinik für Rheumatologie, Düsseldorf, Germany, ⁴Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, ⁵Uniklinik Düsseldorf, Düsseldorf, Germany, ⁶University Hospital of Düsseldorf, Düsseldorf, Germany, ⁷Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁸University Hospital Düsseldorf, Dusseldorf, Germany, ⁹Universitätsmedizin Mainz, Mainz, ¹⁰University Hospital Düsseldorf, Düsseldorf, Germany, ¹¹Bergisches Rheuma-Zentrum, Krankenhaus St Josef, Wuppertal, Germany, ¹²HELIOS St. Elisabeth Clinic Oberhausen, University Witten-Herdecke, Oberhausen, Germany, ¹³Thoraxklinik, University of Heidelberg, Heidelberg, ¹⁴Universitétsklinikum Heidelberg, Heidelberg, Germany, ¹⁵University Hospital Erlangen, Erlangen, Germany, ¹⁶Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany, ¹⁸University Hospital Düsseldorf, Düsseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) possesses the highest case-related mortality of all rheumatic diseases. B cell-targeting, including CD19-targeting CAR-T cells, has shown efficacy but failed to…
Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 2664 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
YOSHINOBU KOYAMA¹, KENTA SHIDAHARA², YU NAKAI², YOSHIHARU SATO³ and YOSHINORI NISHIURA², ¹Japanese Red Cross Okayama Hospital, Okayama, Okayama, Japan, ²Japan Red Cross Okayama Hospital, Okayama-shi, Okayama, Japan, ³DNA Chip Research Inc., Kawasaki-shi, Kanagawa, Japan
Background/Purpose: Interferons (IFNs) play critical roles in systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), where heightened type I IFN signaling is a hallmark. Elevated…
Abstract Number: 2486 • ACR Convergence 2025
In vitro antifibrotic effects of nerandomilast on cell types relevant to intestinal remodeling and fibrosis in systemic sclerosis
Chang Zeng¹, Leslie Amador¹, Daniela Schloesser¹, Chantelle Simone-Roach¹, Kristen Hall¹, LeeAnne Daley¹, Andrew Mikosz¹, Jochen Schmitz¹, David Ebenezer¹, Peter Nickolaus², Kremena Simitchieva³ and Karim El Kasmi¹, ¹Immunology & Respiratory Disease Research, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, ²Immunology & Respiratory Disease Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ³Inflammation Medicine, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder marked by immune dysregulation, vasculopathy, and progressive fibrosis affecting the skin and multiple internal organs, including…
Abstract Number: 1874 • ACR Convergence 2025
Neutrophil Extracellular Trap-Rich Systemic Sclerosis Plasma Promotes Microvascular Endothelial Cell Proliferation and Migration: Implications for Aberrant Angiogenesis
Wenying Liang¹, James St. Clair¹, Pei-Suen Tsou², John Varga², Jason S. Knight², Dinesh Khanna² and Ramadan Ali³, ¹University of Michigan, Ann arbor, ²University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arobr, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a systemic disease characterized by fibrosis, autoimmunity, and vasculopathy. Neutrophil extracellular traps (NETs) are web‐like chromatin…
Abstract Number: 1584 • ACR Convergence 2025
Evaluation of Adverse Childhood Experiences in Systemic Sclerosis: Prevalence and Patient Characteristics
Samuel Good¹, Nahal Ghanoongooi¹, Ju Young Lee², Arissa Young³ and Elizabeth Volkmann¹, ¹David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Division of Rheumatology, Los Angeles, CA, ²David Geffen School of Medicine at University of California, Los Angeles, Department of Medicine, Los Angeles, CA, ³UCLA, Los Angeles, CA
Background/Purpose: There is growing evidence that trauma, and in particular adverse childhood experiences (ACEs), play a role in the pathogenesis and exacerbation of systemic autoimmune…
Abstract Number: 1556 • ACR Convergence 2025
Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Alicia Hinze¹, Nishanth Katurkuri², Robert Vassallo², Ami Shah³, Ryan Lennon², Brian Bartholmai² and Cynthia Crowson⁴, ¹Mayo Clinic - Rochester, MN, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Johns Hopkins Rheumatology, Baltimore, MD, ⁴Mayo Clinic, Stewartvillle, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable--some patients experience progressive loss of lung function while others…
Abstract Number: 0972 • ACR Convergence 2025
Prominent endothelial senescence in systemic sclerosis skin
Poulami Dey¹, William D Brodie², Megan N Mattichak³, Alexander Cai³, Qi Wu⁴, Johann Gudjonsson⁵, Dinesh Khanna⁵, John Varga⁵ and Pei-Suen Tsou⁵, ¹Michigan Medicine, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴Michigan Medicine, Ann Arbor, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…
Abstract Number: 0703 • ACR Convergence 2025
Trends and Disparities in Systemic Sclerosis-related Mortality Rates in the United States from 1999 to 2023
Nicolas Barnechea Alvarado¹, Khadija Mohib¹, Rameez Qasim² and Muhammad Ali³, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³Dow International Medical College, Karachi, Sindh, Pakistan
Background/Purpose: Systemic sclerosis is one of the most fatal rheumatologic diseases, with significantly higher mortality rates compared to the general population, likely due to its…
Abstract Number: 0676 • ACR Convergence 2025
Engineered glove for the objective assessment of hand dexterity in patients with systemic sclerosis: correlations with clinical features, nailfold videocapillaroscopy, and high frequency skin ultrasonography
Alberto Sulli¹, Elvis Hysa², Paolo Clini³, Emanuele Gotelli⁴, Tamara Vojinovic⁵, Carmen Pizzorni¹, Ali Jaffal³, Sabrina Paolino¹, Rosanna Campitiello³, Vanessa Smith⁶ and Maurizio Cutolo³, ¹University of Genoa, Genova, Italy, ²University of Genoa, Genoa, Italy, ³University of Genova, Genova, Italy, ⁴University of Genoa, Genoa, Liguria, Italy, ⁵University of Genoa, Genova, ⁶Ghent University Hospital, Gent, Belgium
Background/Purpose: Hand disability is a major feature of systemic sclerosis (SSc), driven by skin thickening and joint contractures, with significant impact on quality of life.…
Abstract Number: 0843 • ACR Convergence 2025
Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy Manufactured Using a Next-Generation Process: Updated Data From a Phase 1 Trial in Patients With Systemic Sclerosis
Dinesh Khanna¹, David Korman², Elana Bernstein³, Neil Kramer⁴, Vikas Majithia⁵, Philip J. Mease⁶, Georg Schett⁷, Jacques Azzi⁸, Richard Nash⁹, Ran Reshef³, Mohammad Cherry¹⁰, Ernesto Ayala⁵, Matthew Schwede¹¹, Monalisa Ghosh¹², Fabian Müller¹³, Alisha Desai¹⁴, San-San Ou¹⁵, Sharmila Das¹⁴, Jerill Thorpe¹⁶, Melissa Harnois¹⁴, Alexis Melton¹⁶, Ashley Koegel¹⁶ and Margrit Wiesendanger⁸, ¹University of Michigan, Ann Arbor, MI, ²Mountain Rheumatology, Denver, CO, ³Columbia University Irving Medical Center, New York, NY, ⁴Overlook Medical Center; Atlantic Medical Group, Atlantic Health System, Summit, NJ, ⁵Mayo Clinic Hospital, Jacksonville, FL, ⁶Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Icahn School of Medicine at Mount Sinai, New York, NY, ⁹Health One Cares, Denver, CO, ¹⁰Atlantic Health System, Morristown, NJ, ¹¹Swedish Cancer Institute, Seattle, WA, ¹²C. S. Mott Children's Hospital University of Michigan Health, Ann Arbor, MI, ¹³University Hospital of Erlangen, Erlangen, Germany, ¹⁴Bristol Myers Squibb, Princeton, NJ, ¹⁵Bristol Myers Squibb, Seattle, WA, ¹⁶Bristol Myers Squibb, Princeton
Background/Purpose: BMS-986353 (CC-97540) is an investigational CD19-directed T-cell therapy expressing the chimeric antigen receptor (CAR) used in globally-approved lisocabtagene maraleucel; it is manufactured via the…
Abstract Number: 2656 • ACR Convergence 2025
Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Claudia Iannone¹, Marco Di Battista², Maria Rosa Pellico³, ilaria Magi⁴, Antonina Minniti⁵, Giuseppe Armentaro⁴, Silvia Cavalli⁴, Manuel Sette⁴, Laura Giudice⁴, Cristina Bochicchio⁴, Alessandra Della Rossa⁶, Antonio Gaetano Tavoni⁷, Fabio Cacciapaglia⁸, Stefano Stano⁹, Martina Orlandi¹⁰, Dilia Giuggioli¹¹, Marta Mosca¹², Roberto Caporali¹³ and Nicoletta Del pAPA³, ¹University of Milan, Gaetano Pini CTO, Milano, Milan, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³ASST Pini-CTO, Clinical Rheumatology Unit, Milano, Italy, ⁴ASST Pini-CTO, Clinical Rheumatology Unit, Milan, Italy, ⁵ASST Gaetano Pini, milano, Milan, Italy, ⁶Rheumatology Unit, University of Pisa, Milan, Italy, ⁷Clinical Immunology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Milan, Italy, ⁸Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari & Department of Medicine LUM "G. De Gegnnaro" University, Casamassima (Bari) - Italy, Bari, Italy, ⁹⁶. Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy, ¹⁰Rheumatology Unit, Department of Medical and Surgical Sciences for Children and Adults, University Hospital of Modena and Reggio Emilia School of Medicine, Italy., modena, Italy, ¹¹Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, Modena, Italy, ¹²University of Pisa, Pisa, Pisa, Italy, ¹³University of Milan and ASST Gaetano Pini-CTO, Milano, Italy
Background/Purpose: Digital ulcers (DUs) affect approximately 50% of SSc patients, causing significant pain and disability. Current management involves both systemic and local therapies. However, the…
Abstract Number: 2484 • ACR Convergence 2025
Phenotype of systemic sclerosis patients with positive anti–NOR-90 antibodies
Javier Narváez¹, Santos Castañeda², Montserrat Roig Kim³, Martí Aguilar-Coll⁴, Laia De Daniel Bisbe³, Marina Dueñas⁵, Cristina Valero⁶, Francisco Morandeira⁷, Miguel A. González-Gay⁸ and Joan Miquel Nolla³, ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ³Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain, ⁴Department of Rheumatology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Department of Rheumatology.Hospital Universitario de la Princesa, Madrid, Spain, ⁶Hospital de la Princesa, Madrid, Spain, ⁷Department of Immunology. Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain
Background/Purpose: To analyze the clinical associations of anti-Nucleolar Organizer Region 90 antibodies (NOR90) antibodies in patients with systemic sclerosis (SSc)Methods: Cross-sectional study of NOR90-positive SSc…
Abstract Number: 1873 • ACR Convergence 2025
TGF-β-Driven Mitochondrial Stress Activates cGAS-STING Signalling via Impaired Mitophagy in Systemic Sclerosis Endothelial Cells
Stefano Di Donato¹, Ceclie Bordes², Claude Lalou², agathe Depaire², John Tchen², Charlene Lhuissier², damien Brisou², Vanja Sisirak², Johan Garaude², Christopher Wasson³, Rebecca Ross⁴, Francesco Del Galdo³ and Marie-Elise Truchetet⁵, ¹University of Leeds, Canosa Sannita, Chieti, Italy, ²University of Bordeaux, Bordeaux, France, ³University of Leeds, Leeds, United Kingdom, ⁴Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁵Bordeaux University Hospital, Bordeaux, France
Background/Purpose: Emerging evidence implicates mitochondrial dysfunction as a contributor to tissue fibrosis in systemic sclerosis (SSc) (1). Endothelial cells, which are a key player in…
Abstract Number: 1583 • ACR Convergence 2025
Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
Patompong Ungprasert¹ and Paul Kroner², ¹Cleveland Clinic, Cleveland, OH, Cleveland Heights, OH, ²Riverside Health System, Newport News, VA
Background/Purpose: The inpatient epidemiology, morbidity, mortality, and healthcare expenditures of patients with systemic sclerosis (SSc) are not well-characterized. This study aims to utilize a nationwide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].